Evolus
We're Evolus. Making the beauty experience delightful and achievable for everyone!
- Est. revenue
- $20M–$50M
- Total raised
- $574M
- Latest round
- Post-IPO Debt
- Employees
- 406
Funding & revenue at Evolus
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Estimated annual revenue
$20M–$50M
Modeled range, not company-reported
Total capital raised
$574M
2 known investors
Latest round
Post-IPO Debt · $150M
May 2025
Publicly traded
EVOLUS, EOLS
IPO Feb 2018
Investors
Oxford Finance LLCPharmakon Advisors
Growth signals
How fast Evolus is adding people, roles, and audience.
Employees
406
Reported band 201-500
LinkedIn followers
33.2K
+25.2% year over year
Headcount change
- MoM
- -2.4%
- QoQ
- -2.6%
- 6mo
- +0.2%
- YoY
- +4.6%
- 2yr
- +13.1%
-10 people
-11 people
+1 people
+18 people
+47 people
Team composition
Where Evolus concentrates its people — a read on which function a fractional leader would plug into.
By function
- Business Development11528%
- Sales6817%
- Healthcare Services307%
- Marketing236%
- Human Resources205%
- Operations184%
- Accounting174%
- Education164%
By region
- United States292
- California, United States144
- Los Angeles Metropolitan Area117
- Newport Beach, CA31
- United Kingdom29
- Italy24
Inside Evolus
What the business focuses on, where it operates, and how employees rate it.
Categories
BiotechnologyHealth CarePharmaceuticalBiotech & PharmaceuticalsPharmaceutical and biotechnology
Markets
NASDAQ
Competitors
Companies in the same market as Evolus.
http://www.evansbrewco.comhttps://evline.iohttp://www.dermrochester.com/https://www.evolve-emod.comhttp://www.evolink.comhttp://www.formevo.co.ukhttps://www.eweev.comhttp://www.globalevolution.comhttps://www.elliot-collective.com/https://www.ocrevus.comhttp://www.evripos.cahttp://www.elevenpointtwo.inhttp://www.nevs.comhttps://www.getevoai.apphttp://www.evokinnovations.comhttp://orveonglobal.com
Evolus in the news
Recent coverage picked up alongside the firmographic refresh.
- Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future
Sep 2026
- Evolus president & CEO David Moatazedi sells $950,018 in shares
Sep 2026
- Anti-Aging Drugs Market Poised for US$ 102.5 Bn Valuation by 2031, Growing at 6.25% CAGR, New Report by Wissen Research
Sep 2026
- Evolus Officer Sold Shares Worth Over $950K
Sep 2026
- Anti-Aging Drugs Market Poised for US$ 102.5 Bn Valuation by 2031, Growing at 6.25% CAGR, New Report by Wissen Research
Sep 2026
- Insider at Evolus (NASDAQ: EOLS) moves to sell nearly $1M in stock
Sep 2026
Jobs
1
Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed September 25, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent Evolus, you can claim this page to manage and enhance it.